Home/Filings/4/0000899243-18-009444
4//SEC Filing

Novartis Institutes for BioMedical Research, Inc. 4

Accession 0000899243-18-009444

CIK 0001661998other

Filed

Apr 3, 8:00 PM ET

Accepted

Apr 4, 4:24 PM ET

Size

9.1 KB

Accession

0000899243-18-009444

Insider Transaction Report

Form 4
Period: 2018-04-02
Transactions
  • Conversion

    Common Stock

    2018-04-02+1,979,2261,979,226 total
  • Conversion

    Series B Preferred Stock

    2018-04-021,979,2260 total
    Common Stock (1,979,226 underlying)
Footnotes (2)
  • [F1]The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Common Stock held directly by NIBRI.
  • [F2]Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

Issuer

Homology Medicines, Inc.

CIK 0001661998

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001673852

Filing Metadata

Form type
4
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 4:24 PM ET
Size
9.1 KB